Literature DB >> 28290344

Is VMAT beneficial for patients undergoing radiotherapy to the head and neck?

J Osborn1.   

Abstract

Volumetric Intensity-Modulated Arc Therapy (VMAT) offers solutions to the time consuming, higher monitor unit (MU) delivery of Intensity-Modulated Radiotherapy (IMRT) for patients undergoing radiotherapy for head and neck cancer (HNC). Thus the aim was to determine whether VMAT would be beneficial for these patients. The majority of literature was planning comparative studies with only two studies on early clinical experience. Main themes arising from literature were conformity and homogeneity, organs at risk (OAR), MU and delivery time. VMAT provides plans with similar conformity, better homogeneity and results for improved sparing of OAR compared to IMRT. Thus it is clear that VMAT would be able to match the performance of IMRT plans, with the ability to treat patients in a short space of time and less MU. There is little clinical data on the side effects of VMAT, and more is needed to further evaluate the efficacy of VMAT. Overall these are encouraging results of VMAT for patients with HNC. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; IMRT; VMAT; Volumetric Modulated Arc Therapy

Mesh:

Year:  2016        PMID: 28290344     DOI: 10.1016/j.radi.2016.08.008

Source DB:  PubMed          Journal:  Radiography (Lond)        ISSN: 1078-8174


  8 in total

Review 1.  Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer.

Authors:  Luca Cozzi; Frank Lohr; Antonella Fogliata; Davide Franceschini; Fiorenza De Rose; A R Filippi; Gabriele Guidi; Valentina Vanoni; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2017-12-19       Impact factor: 3.481

2.  Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: A comparative analysis of dosimetry for target volume and organs at risk.

Authors:  Hironori Akiyama; Csilla Pesznyák; Dalma Béla; Örs Ferenczi; Tibor Major; Csaba Polgár; Zoltán Takácsi-Nagy
Journal:  Radiol Oncol       Date:  2018-11-12       Impact factor: 2.991

3.  Volumetric modulated arc therapy treatment planning based on virtual monochromatic images for head and neck cancer: effect of the contrast-enhanced agent on dose distribution.

Authors:  Riho Komiyama; Shingo Ohira; Naoyuki Kanayama; Tsukasa Karino; Hayate Washio; Yoshihiro Ueda; Masayoshi Miyazaki; Teruki Teshima
Journal:  J Appl Clin Med Phys       Date:  2019-10-21       Impact factor: 2.102

Review 4.  Dosimetric justification for the use of volumetric modulated arc therapy in head and neck cancer-A systematic review of the literature.

Authors:  Nikolett Buciuman; Loredana G Marcu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-16

5.  Oral Candida spp. Colonisation Is a Risk Factor for Severe Oral Mucositis in Patients Undergoing Radiotherapy for Head & Neck Cancer: Results from a Multidisciplinary Mono-Institutional Prospective Observational Study.

Authors:  Cosimo Rupe; Gioele Gioco; Giovanni Almadori; Jacopo Galli; Francesco Micciché; Michela Olivieri; Massimo Cordaro; Carlo Lajolo
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

Review 6.  Head and neck cancer: improving outcomes with a multidisciplinary approach.

Authors:  Cristiana Lo Nigro; Nerina Denaro; Anna Merlotti; Marco Merlano
Journal:  Cancer Manag Res       Date:  2017-08-18       Impact factor: 3.989

7.  Adaptive radiotherapy for head and neck cancer reduces the requirement for rescans during treatment due to spinal cord dose.

Authors:  Louise Belshaw; Christina E Agnew; Denise M Irvine; Keith P Rooney; Conor K McGarry
Journal:  Radiat Oncol       Date:  2019-11-01       Impact factor: 3.481

8.  Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.

Authors:  Chengqiang Li; Cheng Tao; Tong Bai; Zhenjiang Li; Ying Tong; Jian Zhu; Yong Yin; Jie Lu
Journal:  BMC Cancer       Date:  2021-03-10       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.